Browse > Article

Guided Selection of Human Antibody Light Chains against TAG-72 Using a Phage Display Chain Shuffling Approach  

Kim, Sang-Jick (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Hong, Hyo-Jeong (Therapeutic Antibody Research Center, Korea Research Institute of Bioscience and Biotechnology)
Publication Information
Journal of Microbiology / v.45, no.6, 2007 , pp. 572-577 More about this Journal
Abstract
To enhance therapeutic potential of murine monoclonal antibody, humanization by CDR grafting is usually used to reduce immunogenic mouse residues. Most humanized antibodies still have mouse residues critical for antigen binding, but the mouse residues may evoke immune responses in humans. Previously, we constructed a new humanized version (AKA) of mouse CC49 antibody specific for tumor-associated glycoprotein, TAG-72. In this study, to select a completely human antibody light chain against TAG-72, guided selection strategy using phage display was used. The heavy chain variable region (VH) of AKA was used to guide the selection of a human TAG-72-specific light chain variable region (VL) from a human VL repertoire constructed from human PBL. Most of the selected VLs were identified to be originated from the members of the human germline VK1 family, whereas the VL of AKA is more homologous to the VK4 family. Competition binding assay of the selected Fabs with mouse CC49 suggested that the epitopes of the Fabs overlap with that of CC49. In addition, they showed better antigen-binding affinity compared to parental AKA. The selected human VLs may be used to guide the selection of human VHs to get completely human anti-TAG72 antibody.
Keywords
monoclonal antibody; phage display; TAG-72; chain shuffling; guided selection;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 2
연도 인용수 순위
1 Burton, D.R., C.F. Barbas, 3rd, M.A. Persson, S. Koenig, R.M. Chanock, and R.A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88, 10134-10137
2 Figini, M., L. Obici, D. Mezzanzanica, A. Griffiths, M.I. Colnaghi, G. Winter, and S. Canevari. 1998. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res. 58, 991-996   PUBMED
3 Jespers, L.S., A. Roberts, S.M. Mahler, G. Winter, and H.R. Hoogenboom. 1994. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technol. 12, 899-903   DOI
4 Kashmiri, S.V., L. Shu, E.A. Padlan, D.E. Milenic, J. Schlom, and P.H. Hand. 1995. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14, 461-473   DOI   ScienceOn
5 Kim, S.J., M.H. Jang, J.T. Stapleton, S.O. Yoon, K.S. Kim, E.S. Jeon, and H.J. Hong. 2004. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology 318, 598-607   DOI   ScienceOn
6 Tamura, M., D.E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S.V. Kashmiri. 2000. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164, 1432-1441   DOI   PUBMED
7 Iwahashi, M., D.E. Milenic, E.A. Padlan, R. Bei, J. Schlom, and S.V. Kashmiri. 1999. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol. Immunol. 36, 1079-1091   DOI   ScienceOn
8 Yoon, S.O., T.S. Lee, S.J. Kim, M.H. Jang, Y.J. Kang, J.H. Park, K.S. Kim, H.S. Lee, C.J. Ryu, N.R. Gonzales, S.V. Kashmiri, S.M. Lim, C.W. Choi, and H.J. Hong. 2006. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 281, 6985-6992   DOI   ScienceOn
9 Thor, A., R. Muraro, F. Gorstein, N. Ohuchi, M. Viglione, C.A. Szpak, W.W. Johnston, and J. Schlom. 1987. Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. Cancer Res. 47, 505-512   PUBMED
10 Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, and G. Winter. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597   DOI
11 Thor, A., N. Ohuchi, C.A. Szpak, W.W. Johnston, and J. Schlom. 1986. Distribution of oncofetal antigen tumor-associated glycoprotein- 72 defined by monoclonal antibody B72.3. Cancer Res. 46, 3118-3124   PUBMED
12 Figini, M., J.D. Marks, G. Winter, and A.D. Griffiths. 1994. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J. Mol. Biol. 239, 68-78   DOI   ScienceOn
13 Divgi, C.R., A.M. Scott, S. Gulec, E.K. Broussard, N. Levy, C. Young, P. Capitelli, F. Daghighian, J.M. Williams, and R.D. Finn. 1995b. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin. Cancer Res. 1, 1503-1510   PUBMED
14 Watzka, H., K. Pfizenmaier, and D. Moosmayer. 1998. Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire. Immunotechnology 3, 279-291   DOI   ScienceOn
15 Gonzales, N.R., E.A. Padlan, R. De Pascalis, P. Schuck, J. Schlom, and S.V. Kashmiri. 2003. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol. Immunol. 40, 337-349   DOI   ScienceOn
16 De Pascalis, R., N.R. Gonzales, E.A. Padlan, P. Schuck, S.K. Batra, J. Schlom, and S.V. Kashmiri. 2003. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin. Cancer Res. 9, 5521-5531   PUBMED
17 Divgi, C.R., A.M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R.D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu, J. Schlom, and S.M. Larson. 1995a. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med. 36, 586-592
18 Pavlinkova, G., D. Colcher, B.J. Booth, A. Goel, and S.K. Batra. 2000. Pharmacokinetics and biodistribution of a light-chainshuffled CC49 single-chain Fv antibody construct. Cancer Immunol. Immunother. 49, 267-275   DOI
19 Mulligan, T., J.A. Carrasquillo, Y. Chung, D.E. Milenic, J. Schlom, I. Feuerstein, C. Paik, P. Perentesis, J. Reynolds, and G. Curt. 1995. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1, 1447-1454   PUBMED
20 Beiboer, S.H., A. Reurs, R.C. Roovers, J.W. Arends, N.R. Whitelegg, A.R. Rees, and H.R. Hoogenboom. 2000. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. J. Mol. Biol. 296, 833-849   DOI   ScienceOn
21 Divgi, C.R., A.M. Scott, K. McDermott, P.S. Fallone, S. Hilton, K. Siler, N. Carmichael, F. Daghighian, R.D. Finn, A.M. Cohen, J. Schlom, and S.M. Larson. 1994. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl. Med. Biol. 21, 9-15   DOI   ScienceOn
22 Persson, M.A., R.H. Caothien, and D.R. Burton. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA 88, 2432-2436